U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT07608796) titled 'JAK Signaling in Depression and Cognition in Male Football Players' on May 20.
Brief Summary: This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 10 years of organized football. This will be evaluated using a medication called baricitinib that blocks one aspect of inflammation.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Depressive Symptoms
Cognitive Symptom
Intervention:
DRUG: Baricitinib
Baricitinib is an orally administered, selective inhibitor of Janus kinase (JAK) 1 and 2. It reduces cytokine-...